- Home
- DUKR vs PLUR Comparison
DUKR vs PLUR Comparison
Compare DUKR & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DUKR | PLUR |
|---|---|---|
| Founded | N/A | 2001 |
| Country | Israel | Israel |
| Employees | N/A | 142 |
| Industry | Aerospace | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.1M | 18.5M |
| IPO Year | 2015 | 2001 |
Fundamental Metrics
Financial Performance| Metric | DUKR | PLUR |
|---|---|---|
| Price | $5.31 | $1.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 11.7K | ★ 15.9K |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.78 |
| EPS | ★ N/A | N/A |
| Revenue | $377,000.00 | ★ $1,336,000.00 |
| Revenue This Year | N/A | $97.38 |
| Revenue Next Year | N/A | $293.97 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 249.07 | ★ 309.82 |
| 52 Week Low | $4.75 | $1.45 |
| 52 Week High | $7.41 | $5.48 |
Technical Indicators
Market Signals| Indicator | DUKR | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 45.97 | 47.81 |
| Support Level | $4.86 | $1.56 |
| Resistance Level | $5.89 | $1.86 |
| Average True Range (ATR) | 0.44 | 0.10 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 41.01 | 56.43 |
Price Performance
Historical ComparisonAbout PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.